JP Morgan assesses the Specialty Pharmaceuticals sector, highlighting the resurgence of interest in new product launches. While the core fundamentals have strengthened, overall growth remains modest. The analyst offers insights into specific companies, providing ratings and outlining potential opportunities and concerns.